retatrutide efficacy clinical trials A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Retatrutide approval: FDA status, clinical

New non-surgical patients must reside in Arizona

This does not mean every patient has to give up alcohol

PMID: 38302593 | doi:10.1038/s41366-024-01473-y Sanyal AJ et al

Safety and Side Effect Profile Both compounds belong to the same general drug class and share a broadly similar side effect profile, largely gastrointestinal in nature

Other concerning symptoms include: Signs of dehydration (decreased urination, dizziness, extreme thirst) Persistent diarrhea lasting more than 48 hours Blood in stool or vomit Unexplained weight loss beyond expected therapeutic effects Severe constipation unresponsive to standard measures New or worsening heartburn or reflux symptoms Symptoms of gallbladder disease (right upper abdominal pain, especially after meals, fever, or jaundice) Signs of possible bowel obstruction or ileus (severe abdominal distension, inability to pass gas or stool) Before starting digestive enzyme supplements or any over-the-counter products, patients should discuss this decision with their healthcare provider or pharmacist

Evans M, McEwan P, O'Shea R, George L